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Introduction
A major issue in research has been in the concept ofIt is a privilege to introduce the contributions presented
inflammation in hemodialysis. Inflammation and outcome,at the First International Conference on New Insights in
cardiovascular risk and malnutrition were discussed. Oxi-End-Stage Renal Disease held in Madrid on November
dative stress as a strong cofactor for the development of18–20, 2001. The aim of the Conference and these pro-
complications related to long-term hemodialysis such asceedings is to provide the scientific community with some
atherosclerosis, amyloidosis, malnutrition, anemia and in-of the latest contributions in the field of chronic kidney
fection was reviewed. Prevention of reactive oxygen spe-disease. We were able to assemble a group of outstanding
cies (ROS) overproduction might be achieved by improv-scientists and clinicians who are actively involved in the
ing dialysis biocompatibility, an important componentcare of end-stage renal disease (ESRD) patients.
of adequate dialysis, and completed by antioxidant sup-Presentations were organized into six main sessions:
plementation. Patients with ESRD present with a deteri-Predialysis issues; Anemia in predialysis and dialysis pa-
orating immune response reflected in their greater sus-tients; Chronic renal failure after transplantation; Return
ceptibility to bacterial and viral infections, diseases of theto dialysis; The acute phase inflammatory process in he-
autoimmune system, and neoplasias. Spontaneous apo-modialysis; Technical advances in hemodialysis; and Up-
ptosis and the role of the biocompatibility of the hemodi-date in renal bone disease.
alysis membrane also were reviewedIn the first session, important aspects such as measure-
Technical advances in the treatment of patients withment of renal function in chronic renal failure, slowing
ESRD were presented in this meeting. The clinical im-the progression of renal failure, and the optimal manage-
portance of convective transport and morbidity/mortal-ment in pre-ESRD were covered. The most recent epide-
ity related to dialysis efficiency were discussed. The designmiology and possible reasons of delayed referral, the
of current hemodialyzers needs to optimize the most im-associated negative medical and socio-economic conse-
portant aspect, which concerns the coupling of the struc-quences, and methods to improve the referral pattern
ture of the dialyzer with its function and operational con-over the future years of the disease were discussed.
ditions. The replacement of renal proximal tubule cellThe role of anemia in the development of left ventricu-
function in acute renal failure with a cell therapy devicelar hypertrophy and the influence of target hemoglobin
is a logical therapeutic direction, since the pathophysiol-in morbidity and mortality were the primary focus of
ogy of this disorder is due predominantly to proximalthe anemia in predialysis session, together with optimal
tubule cell injury, apoptosis, and necrosis. Human cell re-target hemoglobin. Darbepoetin alfa, a new therapeutic
nal tubule assist device cartridges maintained viability inagent for the treatment of renal anemia as it has great
an extracorporeal hemoperfusion circuit in series with ametabolic stability in vivo and a terminal half-life after
synthetic hemofilter during CVVH in the clinical setting.intravenous administration that is three times longer than
New advances in the control of renal bone diseasefor intravenous erythropoietin, was presented. Once
were discussed last in this meeting and covered the roleweekly and once every other week dosing can maintain the
of vitamin D analogs and perspectives for treatment ofhemoglobin concentration in patients with renal anemia.
calcimimetic agents. Factors involved in the pathogenesisPresentations in the third session switched the focus
of refractory hyperparathyroidism such as nodular hy-of the symposium to chronic renal failure after trans-
perplasia with decreased levels of vitamin D receptorplantation: which and how much immunosuppression
and calcium sensor receptor or failure to control serumshould be used, hyperlipidemia, and cardiovascular dis-
phosphorus levels were analyzed. Three types of surgicalease. One very important subject highlighted in this ses-
approach have been advocated for the treatment of re-sion related to the return to dialysis after renal trans-
fractory hyperparathyroidism: subtotal parathyroidec-plantation, and illustrated how preventive strategies can
tomy, total parathyroidectomy with parathyroid auto-be implemented in practice to improve the clinical situa-
transplantation and total parathyroidectomy withouttion of patients starting dialysis after graft failure.
autografting. Clinical differences in terms of the control
of hyperparathyroidism, vascular calcifications or meta-
bolic bone disease were discussed.Received for publication January 22, 2002
We are grateful to all of the distinguished contributors
who accepted our request for them to elaborate on their 2002 by the International Society of Nephrology
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area of expertise both in their presentations at the meet- grant. This is not new, because Amgen has always sup-
ported the scientific community to facilitate not onlying and in these published proceedings.
research, but also many forums for scientific interchange.Knowledge must be shared by basic researchers, prac-
We especially thank Ms. Eva Lloberes for her stimulat-tical clinicians, health care providers, and industry to
ing interest.further the innovations in ESRD research and therapy.
During the closing remarks at the end of the Confer-This knowledge will improve long-term survival and pro-
ence, we formalized the promise of organizing a secondvide a better quality of life for our patients with the ulti-
meeting to be held in Co´rdoba in three years time, duemate goal of eradicating the disease. We cannot think
to the kind support of the Fundacio´n Nefrolo´gica. Byof a better journal than Kidney International to dissemi-
that time, there is no doubt that new and relevant basicnate the scientific content of this meeting. The editor, Dr.
and clinical information will be available for improvingSaulo Klahr, favored the publication of this Supplement.
the care of our renal patients.Again, we express our gratitude to Saulo for what we
think was a wise decision. Pedro Aljama, Jose´ Miguel Cruz,
The Conference and publication of its proceedings Angel L. Martı´n de Francisco, Luis Piera,
were possible only because Amgen provided technical and and Fernando Valderra´bano
Guest Editorsfinancial support by way of an unrestricted educational
